173 related articles for article (PubMed ID: 8966363)
21. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
22. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
[TBL] [Abstract][Full Text] [Related]
23. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
24. [Study on the value of tumor markers ProGRP, CYFRA21-1, NSE and CEA in the differential diagnosis of pleural effusion].
Liu Y; Yu L; Lin J
Zhongguo Fei Ai Za Zhi; 2006 Jun; 9(3):273-6. PubMed ID: 21172161
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic utility of carcinoembryonic antigen, neuron-specific enolase and squamous cell carcinoma antigen in malignant pleural effusion].
Sánchez de Cos Escuín J; López Parra S; Disdier Vicente C; Martín Vicente MJ; Masa Jiménez JF; Domínguez Retortillo C
An Med Interna; 1996 Aug; 13(8):369-73. PubMed ID: 8983362
[TBL] [Abstract][Full Text] [Related]
26. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
27. Multiplexing determination of small cell lung cancer biomarkers and their isovariants in serum by immunocapture LC-MS/MS.
Torsetnes SB; Levernæs MS; Broughton MN; Paus E; Halvorsen TG; Reubsaet L
Anal Chem; 2014 Jul; 86(14):6983-92. PubMed ID: 24945626
[TBL] [Abstract][Full Text] [Related]
28. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
29. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
[TBL] [Abstract][Full Text] [Related]
30. [Utility of NSE, ProGRP and LDH in Diagnosis and Treatment
in Patients with Small Cell Lung Cancer].
Peng Y; Wang Y; Li J; Hao X; Hu X
Zhongguo Fei Ai Za Zhi; 2016 Sep; 19(9):590-4. PubMed ID: 27666548
[TBL] [Abstract][Full Text] [Related]
31. Improvement of the diagnosis of the cause of pleural effusion in patients with lung cancer by simultaneous quantification of carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) pleural levels.
Menard O; Dousset B; Jacob C; Martinet Y
Eur J Cancer; 1993; 29A(13):1806-9. PubMed ID: 8260229
[TBL] [Abstract][Full Text] [Related]
32. Enzyme immunoassay of immunoreactive progastrin-releasing peptide(31-98) as tumor marker for small-cell lung carcinoma: development and evaluation.
Aoyagi K; Miyake Y; Urakami K; Kashiwakuma T; Hasegawa A; Kodama T; Yamaguchi K
Clin Chem; 1995 Apr; 41(4):537-43. PubMed ID: 7720242
[TBL] [Abstract][Full Text] [Related]
33. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
34. Carcinomatous and tuberculous pleural effusions. Comparison of tumor markers.
Niwa Y; Kishimoto H; Shimokata K
Chest; 1985 Mar; 87(3):351-5. PubMed ID: 3971760
[TBL] [Abstract][Full Text] [Related]
35. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
36. [Diagnostic value of the combined determination of carcinoembryonic antigen (CEA) in pleural effusion and serum with an enzyme immunoassay (EIA). Sensitivity, specificity and relation to tumor type].
Klech H; Rona G; Hutter C; Bayer PM; Kummer F
Wien Klin Wochenschr; 1986 Sep; 98(17):564-73. PubMed ID: 3020811
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission.
Muley T; Herth FJ; Heussel CP; Kriegsmann M; Thomas M; Meister M; Schneider MA; Wehnl B; Mang A; Holdenrieder S
Tumour Biol; 2024; 46(s1):S219-S232. PubMed ID: 37840518
[TBL] [Abstract][Full Text] [Related]
38. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
39. The significance of NSE and CEA as a differentiation marker for the cellular heterogeneity of small cell lung cancer.
Kobayashi S; Okada S; Hasumi T; Sato N; Fujimura S
Tohoku J Exp Med; 1999 Sep; 189(1):37-49. PubMed ID: 10622207
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]